New rapid anthrax test developed through collaboration between Mayo Clinic and Roche Diagnostics. Test, which provides results in less than one hour, will be made available to United States laboratories

November 05, 2001

ROCHESTER, MINN./INDIANAPOLIS, IND. -- Mayo Clinic has developed a new DNA test to rapidly identify anthrax in human and environmental samples. Roche Diagnostics is making the test widely available to public health agencies, hospital laboratories and reference laboratories in the United States and other countries. The new test can identify the presence of anthrax in less than one hour instead of days.

"The first thing people want to know in a case of suspected exposure is whether the agent was in fact anthrax," says Franklin R. Cockerill, III, M.D., the Mayo Clinic microbiologist who led the development team. "Until now, local labs have been able to quickly determine the presence of a bacterium, but they can't tell whether it is anthrax or not. The current process to identify the presence of anthrax may take several days. The events of the last several weeks require as rapid a response as possible."

Roche plans to give regional and local laboratories the ability to perform rapid DNA testing, eliminating the waiting period currently required at most laboratories to identify anthrax. Thus, a larger number of laboratories will now be able to provide a rapid "yes" or "no" answer.

"This rapid identification will enable doctors to begin more timely treatment of patients who have been exposed to anthrax, and it will more quickly alleviate undue anxiety for people who haven't been exposed," says Dr. Cockerill.

The Mayo Clinic team led by Dr. Cockerill developed the test using Roche's LightCycler® instrument for polymerase chain reaction (PCR)-based assays. To make the test widely available, Roche significantly accelerated production of the reagents needed to run the assay.

"Making this test available in a very short time frame is our contribution to the fight against bioterrorism and is a direct outcome of the excellent cooperation between Roche and Mayo Clinic," says Martin Madaus, President and CEO of Roche Diagnostics Corporation. "Mayo researchers have several years of experience in developing these types of assays. The speed and broad distribution of the LightCycler® made it an ideal platform for developing the anthrax test. By combining our efforts, we were able to make this test available to qualified laboratories only a few weeks after beginning this initiative."

The test materials will be made available to about two dozen geographically dispersed LightCycler®-equipped laboratories. The timing of local availability will vary location to location, but some may be available Nov. 9. Mayo Clinic has been working with the federal government to make the test formula available to federal agencies that request it, and is lending its expertise to state and federal health officials in the wake of the reported cases of anthrax exposure. Roche is working with the FDA to determine requirements for expedited regulatory approval. Initially, tests will be offered to laboratories at no charge.

"People who suspect they have been exposed to anthrax should contact local law enforcement officials, who will assess the situation and take appropriate steps," says Dr. Cockerill. "These officials will investigate possible exposures and, with local laboratories, will determine whether this rapid testing is warranted. Those who are experiencing unusual, flu-like symptoms should contact their physician."

Mayo Clinic recommends that it is best to have specimens tested at the nearest regional location to realize the full advantage of the rapid return of results that the new test offers.

"The time involved in transporting samples to Mayo Clinic also would undermine the main goal of the test, which is rapid identification," says Dr. Cockerill. "That's why we have helped Roche make the test available locally, to speed the preliminary diagnosis and improve patient care. We are pleased that after a few weeks of round-the-clock efforts, that goal has been achieved."
-end-
Contacts: John Murphy
Mayo Clinic
507-538-1385 (days)
507-284-2511 (evenings)
email: newsbureau@mayo.edu

Dennis Coverdale
Roche Diagnostics Corp.
317-521-7431
email: dennis.coverdale@roche.com

Background on Roche Diagnostics --

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-oriented health care groups in the fields of pharmaceuticals, diagnostics and vitamins. The LightCycler® instrument is used in more than 400 United States laboratories and approximately 1,500 worldwide. Roche's products and services address prevention, diagnosis and treatment of diseases, thus enhancing well-being and quality of life. Roche's Diagnostic Division, the world leader in in-vitro diagnostics with a uniquely broad product portfolio, supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories worldwide. Roche Diagnostics Corporation, based in Indianapolis, is the North American headquarters for the diagnostics business of the company.

Mayo Clinic

Related Mayo Clinic Articles from Brightsurf:

Mayo Clinic-led study links obesity with pancreatitis
A study by researchers at Mayo Clinic in Arizona published in the The Journal of Clinical Investigation has found that obesity is not only implicated in chronic diseases such as diabetes, but also in sudden-onset diseases such as pancreatitis.

Mayo Clinic researchers clarify how cells defend themselves from viruses
A protein known to help cells defend against infection also regulates the form and function of mitochondria, according to a new paper in Nature Communications.

Mayo Clinic study looks at changes in outcomes for coronary revascularization
The most common type of heart disease -- coronary artery disease -- affects 6.7% of adults and accounts for 20% of 2 in 10 deaths of adults under age 65.

Mayo Clinic researchers review modern cases of leprosy
Leprosy has a history that has spanned centuries and societies across the globe.

Kidney stones on the rise, Mayo Clinic study finds
Kidney stones are a painful health condition, often requiring multiple procedures at great discomfort to the patient.

Mayo Clinic researchers demonstrate value of second opinions
Many patients come to Mayo Clinic for a second opinion or diagnosis confirmation before treatment for a complex condition.

Mayo Clinic researchers clarify chemo resistance, and perhaps a new therapy
Mayo Clinic scientists have identified a specific protein implicated in drug resistance, as well as a possible therapeutic tool.

Mayo Clinic researchers identify therapy
Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by multiple myeloma.

Mayo Clinic researchers uncover new agents
Mayo Clinic researchers have uncovered three new agents to add to the emerging repertoire of drugs that aim to delay the onset of aging by targeting senescent cells -- cells that contribute to frailty and other age-related conditions.

Mayo Clinic: Reversing physician burnout, using nine strategies to promote well-being
Researchers at Mayo Clinic have been documenting the rise and costs of physician burnout for more than a decade.

Read More: Mayo Clinic News and Mayo Clinic Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.